Large, MPS Flashcards
[Met/MPS]
Mucopolysaccharidoses with typical dysmorphic/coarse features? (3)
MPS 1H (Herler)
MPS 2 (Hunter)
MPS 6 (Maroteaus-Lamy)
[Met/MPS]
Mucopolysaccharidoses with learning difficulties, behavioral problems, and dementia?
MPS 3 (Sanfilippo)
[Met/MPS]
Mucopolysaccharidoses with severe bone dysplasia?
MPS 4 (Morquio)
[Met/MPS]
Mucopolysaccharidoses 1 types and enzyme defect?
Severe or attenuated (Hurler or Scheie, previously)
a-L-iduronidase defect
[Met/MPS]
Mucopolysaccharidoses 2 types and enzyme defect?
Hunter
Iduronate sulfatase defect
[Met/MPS]
Mucopolysaccharidoses 3 name and types?
Sanfilippo A, B, C, D
[Met/MPS]
Mucopolysaccharidoses 4 types and enzyme defect?
Morquio A: Galactose 6-sulfatase
Morquio B: b-galactosidase
[Met/MPS]
Mucopolysaccharidoses 6 types and enzyme defect?
Maroteaux-Lamy
N-acetylgalactosamine 4-sulfatase (arylsulphatase B)
[Met/MPS]
Mucopolysaccharidoses 7 types name?
Sly
[Met/MPS]
Mucopolysaccharidoses 9 types and enzyme defect?
Natowicz
Hyaluronidase
[Met/MPS]
Clinical presentation of untreated severe MPS 1 (Hurler) by age? (4)
At birth: non-specific, umbilical or inguinal hernia, frequent URI
By 1 year: coarse facial features, Gibbus deformity, progressive skeletal dysplasia
By 3 year: intellectual disability, hearing loss, corneal clouding
Death by 10 years of life without treatment
[Met/MPS]
Clinical presentation of untreated attenuated MPS 1 (Hurler)?
- Onset age
- 4 organ systems
Onset between 1-10 years
Hearing loss
Corneal clouding
Respiratory involvement
Cardiac valvular disease
[Met/MPS]
Treatment options for MPS 1 (Hurler)? (2)
Hematopoietic stem cell transplantation with severe MPS 1
Enzyme replacement therapy with Aldurazyme
[Met/MPS]
Less effected symptoms from hematopoietic stem cell transplantation in severe MPS 1? (3)
HSCT has lesser effects on
- the skeletal and joint manifestations
- corneal clouding
- cardiac involvement
[Met/MPS]
Inheritance pattern of MPS 2 (Hunter)?
X-linked
[Met/MPS]
Classification (recently considering) for MPS 2 (Hunter)?
Early progressive and slowly progressive
(Disease has a wide variety, and has a continuum)
[Met/MPS]
Diagnostic biochemical test and genetic test for MPS 1 (Hurler)? (3)
Enzyme activity: the lysosomal enzyme α-L-iduronidase (IDUA)
Elevation of glycosaminoglycan (GAG): dermatan sulfate, heparan sulfate
Gene: IDUA
[Met/MPS]
Clinical presentation of usually seen only in early progressive MPS 2 (Hunter) compared to slowly progressive? (3 organ systems)
CNS: progressive cognitive deterioration
Resp: frequent URI, progressive airway obstruction
Cardiac: valvular disease, cardiomyopathy
[Met/MPS]
Common Clinical presentation of both early progressive and slowly progressive MPS 2 (Hunter)? (6)
Macrocephaly, hydrocephalus
Macroglossia
Conductive and sensorineural hearing loss
Hepatosplenomegaly
Dysostosis multiplex (deposition of lipid like substance in body tissues)
Carpal tunnel syndrome
(No corneal clouding in Hunter)
[Met/MPS]
Diagnostic biochemical test and genetic test for MPS 2 (Hunter)? (3)
Iduronate 2-sulfatase (I2S) enzyme activity
Glycosaminoglycan (GAG): dermatan sulfate, heparan sulfate
Gene: IDS
[Met/MPS]
Treatment options for MPS 2 (Hunter)? (2)
Enzyme replacement therapy with Elaprase
Hematopoietic stem cell transplantation, but no RCT done
[Met/MPS]
What based for classification of MPS 3 (Sanfilippo)?
Based on enzyme defects
MPS IIIA: N-sulphoglucosamine sulphohydrolase (m/c)
MPS IIIB: Alpha-N-acetylglucosaminidase,
MPS IIIC: Heparan-alpha-glucosaminide N-acetyltransferase
MPS IIID: N-acetylglucosamine-6-sulfatase
[Met/MPS]
Clinical presentation of MPS 3 (Sanfilippo)? (3 phases)
Phase 1—developmental delay with recurrent URIs, diarrhea
Phase 2—severe, challenging behavior presents with hyperactivity and aggression, Precocious puberty
Phase 3—further neurologic deterioration, Death occurs by the 20s.
[Met/MPS]
Treatment of MPS 3 (Sanfilippo)?
Supportive care
(HSCT considered not effective, ERT is limited due to BBB, developing intrathecal)